Treatment of Primary CNS Lymphoma ( FTD )

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 2, 2017

Primary Completion Date

March 2, 2019

Study Completion Date

March 2, 2019

Conditions
Primary CNS Lymphoma (PCNSL)
Interventions
DRUG

HD-MTX-Ara-C regimen

"HD-MTX-Ara-C regimen high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine~1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles"

DRUG

FTD regimen

FTD regimen(fotemustine, temozolomide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,temozolomide 150mg/m2 d1-5 po,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 28 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles

Trial Locations (1)

450052

Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
collaborator

Zhengzhou University

OTHER

lead

Mingzhi Zhang

OTHER

NCT05274139 - Treatment of Primary CNS Lymphoma ( FTD ) | Biotech Hunter | Biotech Hunter